SmallCaps
ASX:SNTPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals

SYNTARA ORD

$0.031
$0.001 (3.13%)
Day Range
$0.031 - $0.032
52 Week Range
$0.023 - $0.089
Volume
322.54K
Avg Volume (10D)
554.61K
Market Cap
$50.64M
Price Chart
Market Statistics
Open$0.032
Previous Close$0.032
Day High$0.032
Day Low$0.031
52 Week High$0.089
52 Week Low$0.023
Valuation
Market Cap50.64M
Shares Outstanding1.63B
Price to Book3.25
Trading Activity
Volume322.54K
Value Traded10.32K
Bid$0.031 × 2,441,471
Ask$0.033 × 15,500
Performance
1 Day3.23%
5 Day-3.03%
13 Week0.00%
52 Week-60.00%
YTD-8.57%
Technical Indicators
RSI (14)42.94
50-Day SMA$0.033
200-Day SMA$0.038
Latest News
Syntara advances myelofibrosis trial with Phase 2 data and SNT-5505 FDA fast track designation
Biotechnology

Syntara advances myelofibrosis trial with Phase 2 data and SNT-5505 FDA fast track designation

Clinical-stage drug developer Syntara (ASX: SNT) has hit more milestones with its SNT-5505 blood cancer treatment candidate. The company informed shareholders that it has obtained further positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 in combination with ruxolitinib  (RUX) for the treatment of myelofibrosis. Myelofibrosis is a type of blood cancer […]

1 min read
Colin Hay
Colin Hay